1	Evaluation of Six Commercial and Non-Commercial Colistin Resistance Diagnostics
2	Tumisho Mmatumelo Seipei Leshaba ^a , Masego Mmatli ^a , Lebogang Skosana ^{ab} , Nontombi
3	Marylucy Mbelle ^a , John Osei Sekyere ^{#acd}
4	^a Department of Medical Microbiology, School of Medicine, University of Pretoria, South
5	Africa.
6	^b Department of Medical Microbiology, Tshwane Academic Division, National Health
7	Laboratory Service, Pretoria, South Africa
8	^c Department of Dermatology, School of Medicine, University of Pretoria, South Africa
9	^d Institute of Biomarker Research, Medical Diagnostic Laboratories, Genesis Biotechnology
10	Group, Hamilton, NJ, United States
11	#Address correspondence to Dr. John Osei Sekyere, Department of Dermatology, School of
12	Medicine, University of Pretoria, 0084 Pretoria, South Africa: j.oseisekyere@up.ac.za;
13	jod14139@gmail.com
14	
15	Running head: Evaluation of colistin resistance diagnostic tests.
16	Tweet: "Vitek 2, Sensititre, and ComASP colistin proved superior colistin MIC tests when
17	evaluated among six tests. The Rapid NP test was comparatively efficient with a shorter
18	turnaround time, albeit with higher very major errors."
19	
20	
21	

23 Abstract

Background. Resistance to colistin, a last-reserve antibiotic used for treating drug-resistant
 infections, is increasing globally. This study evaluated six diagnostic tests designed to detect
 colistin-resistant pathogens.

Methods. PCR and broth microdilution assays (BMD) were used to respectively characterize the molecular mechanisms and phenotypic colistin resistance of 142 Gram-negative bacterial isolates and controls. The sensitivity, specificity, positive- and negative-predictive values, major (ME) and very major errors (VME), categorical and essential agreements (EA) of ComASP Colistin, CHROMagar COL-*APSE*, Rapid NP Test, Sensititre, MicroScan, and Vitek 2 were determined with these isolates; the BMD was used as gold standard.

33 Results. The Vitek 2, Sensititre, and ComASP tests were more efficient, albeit with 34 concerning ME and VMEs and low EAs. Sensititre was 100% specific with 0% ME and 35 3.61% VME; Vitek 2 had the least VME (1.25% and 0%) and a low EA (57.50%). ComASP 36 had an EA of 75.35%. MicroScan was highly sensitive (96.55%) but less specific (87.50%), 37 with very below-accetable EAs (48.11%). The CHROMAgar COL-APSE efficiently 38 identified the species with their unique colours but was the least specific (67.80%), with the 39 highest ME (32.20%) and high VME (7.23%). The Rapid NP test had the highest VME 40 (7.84%), producing results within 4 hours with 92.16% sensitivity and 96.08% specificity.

41 Conclusion: Vitek 2, MicroScan, ComASP colistin, and Sensititre are good for determining 42 colistin resistance; the latter two tests are recommendable for low-resourced laboratories. The 43 in-house Rapid NP test has short turnaround time with high efficiency for initial resistance 44 screening.

45 Keywords: colistin resistance; tests; assays; polymyxins; *Enterobacterales*.

47 Introduction

48	Increasing use of carbapenems to treat multidrug-resistant bacterial infections invariably led
49	to the adoption of colistin as a last-reserve antibiotic to counter infections that are resistant to
50	carbapenems [1–3]. Hence, bacteria that are resistant to colistin are increasingly being
51	reported worldwide [4–6]. Resistance to colistin is mediated by several molecular
52	mechanisms, including the mobile colistin resistance (mcr) gene, mutations in the PmrAB and
53	PhoPQ two-component systems, and mutation(s) in the MgrB regulator in Klebsiella
54	pneumoniae [1,2,4,7]. These molecular mechanisms, alongside efflux hyperexpression and
55	porin downregulation, and/or Ecr transmembrane protein mediate phenotype colistin
56	(polymyxin) resistance and heteroresistance [1,8,9].
57	
58	To help clinicians easily detect and monitor colistin-resistant infections, several diagnostic
59	tests and assays, both commercial and non-commercial, have been designed and developed
60	[3,10–12]. Some of these tests (such as the BMD, ComASP TM Colistin, MicroScan, Sensititre
61	and Vitek) are mainly MIC (minimum-inhibitory concentration)-based, measuring only the
62	MICs of the isolates while others are non-MIC—based, purely providing a binary result of
63	resistant or sensitive (such as the CHROMagar COL-APSE, and Rapid NP test) [10-12]. The
64	Rapid NP test was designed to only detect colistin resistance in Enterobacterales and is
65	therefore not useful for all Gram-negative bacteria [10,13]. As a follow-up to previous
66	research [11], we used 142 Gram-negative isolates and controls to evaluate the performance
67	of six colistin resistance diagnostic tests: ComASP Colistin, CHROMagar COL-APSE, Rapid
68	NP test, Sensititre, Vitek 2, and the MicroScan. The BMD remains the gold standard for
69	testing colistin MICs and resistance in bacteria [10]; hence it was used as the reference
70	standard in these evaluation studies.

72 **METHODS**

73 Demographics and source of clinical specimen and isolates

- 74 The evaluation study was conducted on a collection of 134 Gram-negative clinical bacterial
- 75 (GNB) isolates including Enterobacterales (n=103), Acinetobacter baumannii (n=21) and
- 76 *Pseudomonas aeruginosa* (n=10) that were collected from the National Health Laboratory
- 77 Services, Tshwane Academic Division. Eight control strains were also included to make up to
- 78 142: Escherichia coli MC1, E. coli MC2, E. coli MC3, Salmonella group D MC4, Salmonella
- 79 group D MC5, E. coli (mcr-1) EMRC, E. coli ATCC 25922 (EATCC), P. aeruginosa ATCC
- 80 27853 (PATCC). Species identification was performed as part of routine laboratory testing
- 81 using Vitek® 2 automated system (Biomerieux, France) (Table S1). Demographic data such
- 82 as sex, age and sample source were retrieved from the NHLS TrakCare system (Table S1).
- 83 The National Food Institute, Technical University of Denmark provided five mcr-gene control
- 84 strains (four *E. coli* with *mcr*-1, *mcr*-2, *mcr*-3 and *mcr*-4, as well as one *Salmonella* spp. with
- 85 mcr-5) for this study. Antimicrobial susceptibility testing also included one Escherichia coli
- 86 ATCC 25922 and one *P. aeruginosa* ATCC 27853.

87 The labels of the isolates used in this article are known to only the researchers as the original

88 labels were de-identified to maintain the patients anonymity.

89

Broth Microdilution. The reference minimum inhibitory concentration (MIC) of each isolate was determined by manual broth microdilution (BMD) according to ISO standard 20776-1 [14]. Colistin sulfate powder (Glentham Life Sciences, England) was diluted in cationadjusted Mueller Hinton broth (CAMHB) in untreated 96-well microtiter polystyrene plates (Eppendorf, Germany). Dilutions to the MIC range 128-0.25 µg/mL were established. Colistin sensitivity results were interpreted according EUCAST breakpoints (susceptible $\leq 2 mg/L$; resistant >2 mg/L). (https://www.nature.com/articles/s41598-020-63267-2).

97 Detection of *mcr*-genes. All isolates were screened for the presence of *mcr*-1, *mcr*-2, *mcr*-3,
98 *mcr*-4 and *mcr*-5 genes using PCR. The multiplex PCR method previously described by
99 Rebelo *et al.* was used for the screening of *mcr*-genes [15]. The *mcr*-gene control strains
100 supplied by the kind courtesy of Professor Rene S. Hendriksen of the National Food Institute,
101 Technical University of Denmark, were used as positive controls.
102 Vitek 2 system. Besides species identification, the Vitek was also used to determine the MICs
103 of the isolates, using the manufacturer's protocols.

MicroScan. The MicroScan walkaway system (Beckman Coulter, South Africa) was used to determine the sensitivity of the species to colistin using the manufacturer's protocol. Briefly, an overnight culture grown on blood agar was immediately standardized using the the prompt inoculation system provided in the reagent packaging for MicroScan AST (antimicrobial sensitivity testing) and identification (ID) testing. The suspension was placed into the N66 and processed overnight in the MicroScan machine.

110 **ComASPTM Colistin.** ComASPTM Colistin by Liofilchem (Roseto degli Abruzzi, Italy) is a 111 compact panel containing freeze-dried colistin which when diluted should result in two-fold 112 dilutions ranging from 0.25-16 µg/mL [11,16]. The non-automated BMD-based assay allows 113 for four samples to be tested on a single test. The manufacturer's instructions were followed 114 to perform the ComASPTM Colistin test. A 0.5 McFarland suspension of the isolates was 115 prepared in a solution of 250 mL saline and then diluted to 1:20 in saline (Gibco, Thermo 116 Fisher Scientific, USA) to obtain solution A. Solution A (0.4 mL) was added to a tube 117 containing 3.6mL Mueller-Hinton broth provided by the ComASPTM Colistin to obtain 118 solution B. One hundred microliters of solution B were dispensed into each well and the 119 panels were incubated (Vacutec, US) at $36\pm2^{\circ}C$ for 16 to 20 hours in ambient air. Results 120 were read by visually analysing the plates for turbidity.

121 **ChromAgar Col-***APSE*. Fresh 24-hour culture of each isolate was dissolved in saline and 122 adjusted to 0.5 McFarland's standard. This suspension was spread on the ChromAgar Col-123 *APSE* plate and incubated for 18 - 24 hours. The manufacturer's protocol was used 124 throughout this test (https://www.nature.com/articles/s41598-020-63267-2).

125 SensititreTM. SensititreTM (Thermo Fisher Scientific, USA) "FROL" colistin-customised 126 plates were used in this study. A 0.5 McFarland standard in saline was prepared for each 127 isolate (Gibco, Thermo Fisher Scientific, USA). Ten microlitres of the 0.5 McFarland 128 suspension was transferred into an 11 mL tube containing CAMHB with TES buffer for all 129 non-intrinsic Enterobacterales, A. baumanni and P. aeruginosa isolates. However, for 130 Proteus species, Providencia spp. and Morganella morganii 1 µL was transferred into the 11 131 mL CAMHB tube. Each SensititreTM plate constitutes of eight rows with 12 wells, each row 132 allows for the testing of one isolate at different concentrations of colistin. Wells 1-11 contain 133 dehydrated colistin at concentrations of 0.12-128 μ g/mL, respectively. Well 12 represents a 134 positive control and therefore does not contain colistin. Each well was inoculated with 50 μ L 135 of the bacterial broth suspension using a manual pipette. Each plate was then covered with an 136 adhesive seal and incubated (Vacutec, US) at $\pm 35^{\circ}$ C in an aerobic environment. Results were 137 read by visually analysing the plates for turbidity.

138 In-house Rapid Polymyxin NP test.

Rapid Polymyxin NP test is based on the detection of glucose metabolism related to *Enterobacterales* growth in the presence of a defined concentration of colistin [17]. The formation of acid metabolites is shown by a colour change of a pH indicator (red phenol) in less than 4 hours [17,18]. The rapid NP test was performed as described by Nordmann *et al*, 2016 [6,19–21]. To prepare the NP test solution, a 6.25g of CAMHB broth powder and 0.0125g of phenol red powder was added to 225 mL of distilled water. The pH of the solution was then adjusted to 6.7 by adding 1-N HCL in drops after which the solution was

146 autoclaved. A 25 mL of 10% anhydrous D-glucose solution that had been sterilised by 147 filtration was added to the autoclaved CAMHB solution. Colistin stock solution (1280 148 μ g/mL) was diluted to 200 μ g/mL working solution by adding 1 mL of the stock solution to 149 5.4 mL CAMHB. To make colistin-NP test solution, 100 µL of the colistin working solution 150 $(200 \,\mu\text{g/mL})$ was added to 3900 μL NP test solution to get a final concentration of 5 $\mu\text{g/mL}$. 151 The Rapid Polymyxin NP test was carried out in 96 well polystyrene plates (Eppendorf, 152 Germany). A 150 µL of NP test solution alone without colistin was added to wells 1, 3, 5, 7, 153 9 and 11 of each row (A-H) of the 96-well microtiter plates. Wells 2, 4, 6, 8, 10 and 12 154 contained 150 μ L of colistin-NP test solution (5 μ g/mL). *Proteus mirabilis* isolate from our 155 collection was used as a resistant control and Escherichia coli ATCC 25922 was used as a 156 susceptible control.

157 A 3.5 McFarland standard was prepared for each test isolates with sterile 0.85% NaCl 158 solution and used within 15 of preparation. Each Enterobacterales isolate was inoculated (50 159 μ L) in parallel into the two wells, one without colistin and one with colistin. Wells H7-8 were 160 inoculated 50 µL P. mirabilis and wells H9-10 were inoculated with 50 µL E. coli ATCC 161 25922. Wells H11-12 were inoculated with 50 µL of 0.85% NaCl solution. The microtiter plates were incubated for 3 h at 35 ±2, after 3 h of incubation, the isolates were checked for 162 163 change in colour every 15 minutes until 4 h of incubation. The results were read visually 164 where a change in colour of phenol red (orange to bright yellow) indicated growth.

165 **Data analysis**

166 All six antimicrobial susceptibility testing methods were compared to the ISO standard 167 20776-1 BMD. Colistin MIC results were interpreted using EUCAST's breakpoints 168 (susceptible, $\leq 2 \mu g/mL$; resistant, $>2 \mu g/mL$). For each test, the false positives, false 169 negatives, true positives, and true negatives were determined and used for downstream 170 determination of the other performance indices (Table S1). We calculated the rates of

171 essential agreement (EA), categorical agreement (CA), very major error (VME), and major 172 error (ME) using already described methods [11]. Categorical agreement was defined as an 173 agreement in the classification of susceptible or resistant between the evaluated test and the 174 reference BMD. Essential agreement was defined as an MIC value within a 2-fold (one 175 doubling) dilution of the BMD result. A very major error occurred when the tested method 176 interpretation of an isolate was susceptible while the BMD interpretation was resistant for the 177 same isolate. A major error occurred when the investigated method's interpretation was 178 resistant, and the BMD interpretation was susceptible for the same isolate. The sensitivity and 179 specificity of each test were calculated as previously described [11].

180

181 GraphPad Prism 10 was used to calculate the odds ratio and Fisher's exact test to determine182 the significance of each test's results against the BMD.

183

184 **RESULTS**

185 Reference BMD. Reference MICs of all 142 isolates were determined by standard broth 186 microdilution (BMD), either in this study or as standard protocol by the National Health 187 Laboratory Services Tshwane Academic Division. One A. baumannii, 51 Enterobacterales 188 and seven P. aeruginosa isolates were colistin-susceptible with BMD, including one E. coli 189 ATCC 25922 and a P. aeruginosa ATCC 27853 (Table 1). The colistin-resistant isolates by 190 BMD include 59 Enterobacterales, 20 A. baumannii and four P. aeruginosa. Apart from the 191 five mcr control strains, only two isolates, BB2 and EMRC, had mcr-1 genes (Table 1). 192 Isolate BB2 is an A. baumannii with a MIC of 32 µg/mL, while isolate EMRC is an E. coli 193 with a MIC of 4 µg/mL. All eight intrinsically colistin-resistant *Enterobacterales* (Proteus 194 mirabilis, Serratia marcescens, Morganella morganii, Proteus vulgaris, Providencia stuartii, 195 and Ralstonia/Burkholderia pickettii) had MICs \geq 128 µg/mL (Table 1).

196

197 Commercial BMD methods. All 142 isolates were tested on ComASPTM Colistin and 198 SensititreTM. ComASPTM Colistin and SensititreTM both had a satisfactory categorical 199 agreement of 96.48% and 97.18%, respectively. However, ComASPTM Colistin falsely 200 detected one K. pneumoniae (1µg/mL) and one P. aeruginosa (1µg/mL) as colistin-201 susceptible isolates, resulting in 3.40% MEs. SensititreTM accurately identified all colistin-202 susceptible isolates. However, it failed to identify three colistin-resistant isolates, therefore 203 resulting in no MEs and 3.61% VMEs. Most isolates that were not detected by SensititreTM 204 and ComASPTM Colistin had MICs close to the breakpoints (4-8µg/mL). Only one isolate that 205 was not detected by SensititreTM had an MIC >8 μ g/mL i.e., a K. pneumoniae with an MIC of 206 32µg/mL. ComASPTM Colistin had an overall sensitivity and specificity of 96.39% and 207 96.61%, respectively, whereas Sensititre[™] had 96.39% and 100% (Table 2).

Notably, ComASPTM fared better with *Enterobacterales* than with all Gram-negative bacteria as its sensitivity (98.31%), specificity (98.04%), and CA (98.18%) increased while its ME (1.96%) and VMEs (1.72%) reduced (Table 2): the EA, however, increased from 69.09% in *Enterobacterales* to 75.35% in GNB. Sensititre's *Enterobacterales* results were comparably similar to that of its GNB results (Table 2).

Vitek MIC results were obtained for 120 GNB and 94 *Enterobacterales*. Vitek had the highest sensitivity and the second or third highest specificity among GNB and *Enterobacterales*, respectively, for all the tests. It had the highest CA, the second lowest EA (after MicroScan), and one of the lowest VME among the six tests (Table 2). The Microscan was equally highly sensitive but less specific, with the lowest EA (46.11% and 46.91%) among all the MICbased tests. Its sensitivity was 96.55% and 100% for GNB and *Enterobacterales* respectively. The MicroScan's MEs with both GNB and *Enterobacterales* (12.50% and 12.20%) were only

second to that of the CHROMAgar Col-*APSE* (Table 2) and its VMEs were 3.45% (GNB)
and 0% (*Enterobacterales*).

CHROMAgar Col-APSE. A total of 96/142 isolates grew on CHROMAgar Col-*APSE*: BMD
identified 19 of them as colistin susceptible, resulting in 32.20% ME and 67.80% specificity.
Most of the MEs (14/19) were due to *Klebsiella* spp. The chromogenic media detected most
colistin-resistant isolates (77/83), but it also produced a high percentage of VMEs (7.23%),
resulting in a sensitivity of 92.77 %. Among *Enterobacterales* alone, CHROMAgar was less
sensitive (91.53%) and more specific (68.63%), with fewer MEs (31.37%) and CA (80.91%)
than in GNB (Table 2).

Differentiation of the isolated bacteria by the morphological appearance of their colonies was as described by the manufacturer [22]. Metallic blue (*Klebsiella*, *Enterobacter* and *Serratia* spp.), cream white (*Acinetobacter*, *Salmonella* and *Pseudomonas* spp.), pink-red (*E. coli*) colonies were observed (Fig. 1) [22]. Furthermore, *E. coli* could be distinguished as fermenting (blue with pink borders) and non-fermenting strains (pink). Swarming was observed on the *P. mirabilis*-inoculated plate because the plate was not supplemented with pnitrophenyl glycerol as recommended by Abdul Momin *et al* (2017) (Figure 1) [22].

236 In-house Rapid NP Test. Only 102/142 of the isolates that were Enterobacterales were 237 included in this test. This included 51 colistin-susceptible and 51 non-intrinsically colistin-238 resistant *Enterobacterales* isolates. The overall sensitivity and specificity of the in-house 239 Rapid polymyxin NP test was 92.16% and 96.08% respectively. Colistin-resistant isolates 240 that were not detected include one Salmonella spp., two K. pneumoniae and one E. coli, with 241 MICs ranging from 4 – 128 μ g/mL. Two of the false-resistant isolates, also grew on 242 CHROMAgar Col-APSE (Table S1). In this study, most results were positive within two 243 hours of incubation. Six isolates, however, were not detectable after three hours of incubation

but were positive after four hours. Amongst the slow-growing isolates were four *Salmonella*spp., one *E. coli*, and one *E. cloacae*.

246

247 DISCUSSION

248 The proliferation of colistin resistance among GNB has necessitated the development of 249 better diagnostics to quickly and efficiently detect colistin-resistant organisms to control their 250 spread [1,2,4,10,11]. This study evaluated six antimicrobial susceptibility tests that were 251 developed to detect colistin-resistance with efficiency. Broth microdilution is currently the 252 golden standard for colistin susceptibility testing; however, it is considered tedious and 253 difficult [10]. Vitek 2, ComASPTM Colistin, and MicroScan had the best detection 254 (sensitivity) of colistin-resistant isolates (Table 2). When compared with SensititreTM, 255 CHROMagar Col-APSE, the Rapid Polymyxin NP test, ComASPTM Colistin, and MicroScan, 256 Vitek 2 produced the least VMEs at 1.25% and 0% for GNB and Enterobacterales, 257 respectively. This was followed by the MicroScan and ComASP, with VMEs of 3.45% vrs 258 3.57% and 0% vrs 1.96% respectively for all isolates and *Enterobacterales* (Table 2).

259

260 In essence, the Vitek 2, which is common in many well-resourced routine diagnostic 261 microbiology laboratories, is very efficient in detecting colistin resistance albeit its low EA 262 should be considered when using MICs from Vitek 2. Moreover, its initial cost, long 263 turnaround time, and skill required to operate it make it inaccessible to low-resourced 264 laboratories. Although the MicroScan is also highly sensitive with low VMEs (particularly 265 among *Enterobacterales*), its lower specificity and EA, 18 – 24-hour turnaround time, 266 operating skill required, and initial cost are also major disadvantages for low-resourced 267 laboratories [10–12]. The ComASP and Sensititre are two affordable commercial kits that can 268 be adopted in low-resourced laboratories for colistin resistance diagnosis. The Sensititre had

269 100% specificity and 72.54% vrs 71.82% EA for both GNB and *Enterobacterales*, which 270 were the best (with ComASP) among all the six tests. Hence, in terms of cost and required 271 skill, the Sensititre and ComASP are good alternatives for determining the colistin MICs and 272 resistance.

273

274 The EA recorded in this study for both commercial BMD methods is below the recommended 275 EA (\geq 90%) for antimicrobial susceptibility testing systems. The EA did not improve when 276 analysing *Enterobacterales* alone for ComASPTM Colistin, MicroScan, and SensititreTM; 277 Vitek 2, however, had an increase from 57.50% (Gram-negative bacteria) to 59.78% 278 (Enterobacterales) (Tables 1-2). ComASPTM Colistin tended to decrease or increase the MIC 279 of a significant number of colistin-susceptible isolates (29/59) by one two-fold dilution (Table 280 S1). Notwithstanding, this observation did not change the CA between ComASPTM Colistin 281 and the reference BMD.

282

283 In this study, CHROMAgar Col-APSE produced the highest rate of MEs and a high VME 284 second only to that of the in-house Rapid NP test (Tables 1-2), particularly for *Klebsiella* spp. 285 Although the specificity recorded in this study and that of Osei Sekvere *et al* (at 66,67%) 286 agree, two other studies recorded a significantly higher specificity of $\geq 97\%$ [11,22,23]. 287 These discrepancies could be attributed to the different bacterial inoculum concentrations 288 used. Ali et al demonstrated that when a 0.5 McFarland standard inoculum was used, colistin-289 susceptible isolates were able to grow on the media [23], whereas the same isolates were 290 inhibited when the inoculum was diluted to a density of 1×10^5 CFU/mL. Therefore, the high 291 rate of MEs in this present study could be due to the inoculum used being a 0.5 McFarland standard (1.5×10^8 CFU). 292

294 The in-house Rapid Polymyxin NP test was expected to have the best performance for 295 *Enterobacterales.* Even though the test was designed specifically for colistin susceptibility 296 testing on Enterobacterales, its performance was inferior to that of commercial BMD 297 methods (Tables 1-2). Compared with other studies that have achieved a sensitivity of $\geq 97\%$, 298 the overall performance of the in-house Rapid Polymyxin in this study (~92%) is slightly 299 poor [17,18,24]. The CA of all the tests evaluated in this study except for CHROMAgar Col-300 APSE, is within the recommended standard ($\geq 90\%$) for antimicrobial susceptibility testing 301 systems. Nevertheless, except for Vitek 2 for all GNB and MicroScan in only 302 *Enterobacterales*, all the other evaluated tests had an unacceptable VME rate of $\geq 1.5\%$. 303 Only SensititreTM had an acceptable rate of MEs when all isolates were considered, but 304 ComASP[™] Colistin's ME improved when only *Enterobacterales* were examined.

305

306 Therefore, for low-resourced laboratories and research institutions, the in-house Rapid NP 307 test is a better option in terms of turnaround time, cost, and efficiency than the CHROMAgar 308 COL-APSE, except that the latter has advantages of easy use and species identification 309 through its chromogenic compounds. In terms of cost and turnaround time, the CHROMAgar 310 is comparable to the two other commercial MIC tests: Sensititre and ComASP. Nevertheless, 311 the higher efficiency of the former two and their ability to provide actual MICs make them 312 recommendable. Yet, CHROMAgar is easier to use than these two MIC tests and the MICs of 313 ComASP should be used with caution among *Enterobacterales* owing to its 75.35% EA.

314

The statistical odd ratio and *p*-values metrics indicate that the tests, specifically the Vitek 2,

316 SensititreTM, ComASPTM Colistin, MicroScan, and the in-house Rapid NP test, have a

317 relatively high level of performance in identifying both resistant and sensitive isolates among

318 GNB. The PPV and NPV suggest that the tests' predictive values are highly reliable. The

319 odds ratio suggests a very strong association between the test results and the resistance being 320 tested for, indicating that the likelihood of detecting resistant isolates is significantly higher 321 when they are truly resistant, as compared to when they are not. The extremely low p-value 322 indicates that this finding is statistically significant, meaning there's a very small chance that 323 these results could have occurred by random variation alone.

324 CONCLUSION

325 This study discovered that commercial BMD methods had the best overall performance. In

the absence of resources to purchase the Vitek 2 or the MicroScan, we recommend the

327 ComASPTM Colistin and SensititreTM as potential alternative MIC tests for routine colistin 328 antimicrobial susceptibility testing in clinical laboratories. However, isolates with MICs close 329 to the breakpoint may be misinterpreted by commercial BMD tests. As the in-house Rapid 330 NP test had the quickest turnaround time, we recommend it for colistin susceptibility testing 331 on *Enterobacterales*, particularly in laboratories with limited resources and labour skill. 332 Notably, CHROMAgar Col-APSE produced the most errors; with colistin being a last-reserve 333 antibiotic, minimal error is critical. Hence, the use of CHROMAgar Col-APSE should be 334 validated further, possibly with lower inoculum. Notably, all the tests were able to detect 335 colistin resistance in *mcr*-positive strains.

336

Acknowledgements: We are grateful to the staff of the NHLS-TAD for their support and
assistance in collecting and plating the isolates. We hereby regretfully report the death of our
colleague Professor Nontombi Marylucy Mbelle, who died during the course of this
investigation. This work is dedicated to her memory. We are ever grateful to Professor Rene
S. Hendriksen, Ana Rita Bastos Rebelo, and Troels Ronco of the National Food Institute,
Technical University of Denmark, for their donation of the *mcr-1* to *mcr-5* positive controls.

343	Funding:	This work	was funded	by a gran	t from the	National	Health	Laboratory	Service
-----	----------	-----------	------------	-----------	------------	----------	--------	------------	---------

- 344 (NHLS) given to Dr. John Osei Sekyere under grant number GRANT004 94807 and
- 345 GRANT004 94808.
- 346 **Transparency declaration:** The authors declare no conflict of interest.
- 347 Author contributions: TMSL undertook the laboratory investigations, undertook initial
- 348 analysis of the data and drafted the manuscript. MM assisted with the laboratory work.
- 349 BLS assisted with isolates collection and plating. NMM co-supervised the study. JOS
- designed and supervised the study, undertook data analysis, and wrote the manuscript.
- 351 All authors reviewed the final version of the manuscript.
- 352 Ethical approval: The study was approved by the Research Ethics Committee, Faculty of
- Health Sciences, University of Pretoria, under reference number 550/2020. The study
- 354 complied with the ICH-GCP guidelines and the Helsinki declaration.


355 References

- [1] Mmatli M, Mbelle NM, Maningi NE, Osei Sekyere J. Emerging Transcriptional and Genomic
 Mechanisms Mediating Carbapenem and Polymyxin Resistance in Enterobacteriaceae□: a Systematic
 Review of Current Reports. MSystems 2020;5. https://doi.org/10.1128/mSystems.00783-20.
- Mmatli M, Mbelle NM, Osei Sekyere J. Global epidemiology, genetic environment, risk factors and therapeutic prospects of mcr genes: A current and emerging update. Front Cell Infect Microbiol 2022;12. https://doi.org/10.3389/fcimb.2022.941358.
- [3] Mmatli M, Leshaba TMS, Skosana LB, Mbelle NM, Osei Sekyere J. Molecular Screening of Clinical Multidrug-Resistant Gram-Negative Bacteria Shows Endemicity of Carbapenemases, Coexistence of Multiple Carbapenemases, and Rarity of mcr in South Africa. Microb Drug Resist 2022;28:1028–36. https://doi.org/10.1089/MDR.2022.0112.
- Ramaloko WT, Osei Sekyere J. Phylogenomics, epigenomics, virulome and mobilome of Gram-negative
 bacteria co-resistant to carbapenems and polymyxins: a One Health systematic review and meta analyses. Environ Microbiol 2022;24:1518–42. https://doi.org/10.1111/1462-2920.15930.
- Lowe M, Shuping L, Perovic O. Carbapenem-resistant Enterobacterales in patients with bacteraemia at tertiary academic hospitals in South Africa, 2019 2020: An update. South African Med J 2022;112:545–52. https://doi.org/10.7196/SAMJ.2022.V112I8.16351.
- Jayol A, Dubois V, Poirel L, Nordmann P. Rapid Detection of Polymyxin-Resistant Enterobacteriaceae
 from Blood Cultures. J Clin Microbiol 2016;54:2273–7. https://doi.org/10.1128/JCM.00918-16.
- 374 [7] Osei Sekyere J, Reta MA, Fourie PB. Risk factors for, and molecular epidemiology and clinical
 375 outcomes of, carbapenem- and polymyxin-resistant Gram-negative bacterial infections in pregnant
 376 women, infants, and toddlers: a systematic review and meta-analyses. Ann N Y Acad Sci 2021:1–18. https://doi.org/10.1111/nyas.14650.


378 379 380	[8]	Halaby T, Kucukkose E, Janssen AB, Rogers MRC, Doorduijn DJ, van der Zanden AGM, et al. Genomic Characterization of Colistin Heteroresistance in Klebsiella pneumoniae during a Nosocomial Outbreak. Antimicrob Agents Chemother 2016;60:6837–43. https://doi.org/10.1128/AAC.01344-16.
381 382 383	[9]	Poirel L, Jayol A, Nordmann P. Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes. Clin Microbiol Rev 2017;30:557–96. https://doi.org/10.1128/CMR.00064-16.
384 385 386	[10]	Leshaba TMS, Mbelle NM, Osei Sekyere J. Current and emerging polymyxin resistance diagnostics: a systematic review of established and novel detection methods. J Appl Microbiol 2021:jam.15184. https://doi.org/10.1111/jam.15184.
387 388 389	[11]	Osei Sekyere J, Sephofane AK, Mbelle NM. Comparative Evaluation of CHROMagar COL-APSE, MicroScan Walkaway, ComASP Colistin, and Colistin MAC Test in Detecting Colistin-resistant Gram- Negative Bacteria. Sci Rep 2020;10:1–13. https://doi.org/10.1038/s41598-020-63267-2.
390 391	[12]	Osei Sekyere J. Mcr colistin resistance gene: a systematic review of current diagnostics and detection methods. Microbiologyopen 2019;8:e00682. https://doi.org/10.1002/mbo3.682.
392 393 394	[13]	Jayol A, Nordmann P, Lehours P, Poirel L, Dubois V. Comparison of methods for detection of plasmid- mediated and chromosomally encoded colistin resistance in Enterobacteriaceae. Clin Microbiol Infect 2017;pii:S1198-:30291–4. https://doi.org/10.1016/j.cmi.2017.06.002.
395 396 397 398 399	[14]	International Organization for Standardization. Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices - Part 1: Broth micro-dilution reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobi. Biol Eval Med Devices 2019:19. https://www.iso.org/obp/ui/#iso:std:iso:20776:-1:ed-2:v2:en (accessed March 19, 2024).
400 401 402 403	[15]	Rebelo AR, Bortolaia V, Kjeldgaard JS, Pedersen SK, Leekitcharoenphon P, Hansen IM, et al. Multiplex PCR for detection of plasmid-mediated colistin resistance determinants, mcr-1, mcr-2, mcr-3, mcr-4 and mcr-5 for surveillance purposes. Euro Surveill Bull Eur Sur Les Mal Transm = Eur Commun Dis Bull 2018;23. https://doi.org/10.2807/1560-7917.ES.2018.23.6.17-00672.
404 405 406	[16]	Carretto E, Brovarone F, Russello G, Nardini P, El-Bouseary MM, Aboklaish AF, et al. Clinical validation of SensiTest colistin, a broth microdilution-based method to evaluate colistin MICs. J Clin Microbiol 2018;56. https://doi.org/10.1128/JCM.01523-17.
407 408	[17]	Nordmann P, Jayol AAAA, Poirel L. Rapid Detection of Polymyxin Resistance in Enterobacteriaceae. Emerg Infect Dis 2016;22:1038–43. https://doi.org/10.3201/eid2206.151840.
409 410 411	[18]	Mitton B, Kingsburgh C, Kock MM, Mbelle NM, Strydom K. Evaluation of an In-House Colistin NP Test for Use in Resource-Limited Settings. J Clin Microbiol 2019;57. https://doi.org/10.1128/JCM.00501-19.
412 413 414	[19]	Poirel L, Larpin Y, Dobias J, Stephan R, Decousser J-W, Madec J-Y, et al. Rapid Polymyxin NP test for the detection of polymyxin resistance mediated by the mcr-1/mcr-2 genes. Diagn Microbiol Infect Dis 2017;90:7–10. https://doi.org/10.1016/j.diagmicrobio.2017.09.012.
415 416 417	[20]	Jayol AAA, Kieffer N, Poirel L, Guerin F, Guneser D, Cattoir V, et al. Evaluation of the Rapid Polymyxin NP test and its industrial version for the detection of polymyxin-resistant Enterobacteriaceae. Diagn Microbiol Infect Dis 2018;92:90–4. https://doi.org/10.1016/j.diagmicrobio.2018.05.006.
418 419 420	[21]	Nordmann P, Assouvie L, Prod'Hom G, Poirel L, Greub G. Screening of plasmid-mediated MCR-1 colistin-resistance from bacteremia. Eur J Clin Microbiol Infect Dis 2016;35:1891–2. https://doi.org/10.1007/s10096-016-2739-0.
421 422 423	[22]	Abdul Momin MHF, Bean DC, Hendriksen RS, Haenni M, Phee LM, Wareham DW. CHROMagar COL-APSE: a selective bacterial culture medium for the isolation and differentiation of colistin-resistant Gram-negative pathogens. J Med Microbiol 2017;66:1554–61. https://doi.org/10.1099/jmm.0.000602.

- 424 [23] Ali S, Hussain W, Ahmed F, Afzal RK, Mirza I, Khurshid U. ChromagarTM Col-Apse for Detection of 425 Colistin Resistance in Clinical Isolates of Multidrug Resistant Gram Negative Bacilli. J Coll Physicians 426 Surg Pak 2022;32:177–80. https://doi.org/10.29271/JCPSP.2022.02.177.
- 427 [24] Germ J, Seme K, Cerar T, Krizan Hergouth V, Pirs M. Evaluation of two rapid phenotypical tests-Alifax
 428 rapid AST colistin test and Rapid Polymyxin NP test-for detection of colistin resistance in
- 429 Enterobacterales. Eur J Clin Microbiol Infect Dis 2021;40:1749–53. https://doi.org/10.1007/S10096-430 021-04182-W.





8



431

432 Figure 1. Appearance of different bacterial species on the CHROMAagar-col APSE chromogenic media. (A) Bacterial

-

- 433 growth on CHROMAgar Col-APSE showing different colony colours. (B) Swarming by P. mirabilis on CHROMAgar Col-
- 434 APSE

- 436 Table S1. Demographics, species, complete antibiotic resistance results data, and minimum inhibitory concentrations (MICs)
- 437 of the isolates used in this study.

